Skip to main content
RELMADA THERAPEUTICS, INC. logo

RELMADA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · RLMD ISIN · US75954H1005 LEI · 549300217EASRZ9JSF81 US Professional, scientific and technical activities
Open in API
Filings indexed 582 across all filing types
Latest filing 2015-12-14 Board/Management Inform…
Country US United States of America
Listing US RLMD

About RELMADA THERAPEUTICS, INC.

https://www.relmada.com/

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company developing novel therapies. The company's lead program is NDV-01, a sustained-release, intravesical formulation of gemcitabine and docetaxel for the treatment of non-muscle invasive bladder cancer. The formulation is designed for gradual drug release over 10 days to enhance local exposure and minimize systemic toxicity. Relmada's pipeline also includes Sepranolone, which is being developed for compulsive disorders. Following positive proof-of-concept data in Tourette’s syndrome, the company is planning a Phase 2 study of Sepranolone in Prader-Willi Syndrome, a rare genetic disorder.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The content specifically announces the appointment of James Dolan as an advisory partner, which is a management-related update. There are no financial statements or detailed financial data included, and the document is relatively short (2615 characters). This fits the category of Board/Management Information (MANG), which covers announcements of changes in senior management or board members. It is not an Annual Report, Earnings Release, or any other financial report type. Therefore, the correct classification is MANG with high confidence.
2015-12-14 English
CURRENT REPORT
Legal Proceedings Report Classification · 95% confidence The document is a Form 8-K filing with the SEC, titled 'CURRENT REPORT' and dated December 10, 2015. It reports a legal event involving a temporary restraining order issued by a U.S. District Court related to proxy materials and a lawsuit against certain defendants. The content focuses on legal proceedings and court orders rather than financial results, management changes, or shareholder votes. It includes exhibits such as a press release and the court order. Given the nature of the content—legal updates and regulatory compliance related to securities law—and the fact that it is a current report (8-K) describing a legal event, the most appropriate classification is Legal Proceedings Report (LTR). The document is not an annual or quarterly report, earnings release, or other financial report type, nor is it a simple announcement or certification. Therefore, the classification is LTR with high confidence.
2015-12-11 English
DEFINITIVE ADDITIONAL MATERIALS
Remuneration Information Classification · 95% confidence The document is titled 'DEFA14A 1 defa14a121115_relmadathera.htm DEFINITIVE ADDITIONAL MATERIALS' and references Schedule 14A, which is related to proxy statements. It is described as 'Definitive Additional Materials' filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. The content discusses a court order related to proxy materials and mentions the company's 2015 Annual Meeting of Stockholders and the definitive proxy statement filed earlier. The document is clearly related to proxy solicitation and additional materials supplementing the proxy statement. It is not a full annual report, earnings release, or other financial report but rather additional proxy materials. Therefore, the correct classification is 'Remuneration Information' (DEF 14A), which covers reports detailing compensation and proxy-related materials filed under Schedule 14A.
2015-12-11 English
DEFINITIVE ADDITIONAL MATERIALS
Call Transcript Classification · 95% confidence The document is a transcript of a conference call held by Relmada Therapeutics, Inc. on December 10, 2015. It includes detailed discussions by company executives and scientific advisors about clinical study results, drug development programs, and scientific explanations related to their BuTab product. The presence of an operator, multiple speakers, and a Q&A session format are typical features of earnings or corporate conference call transcripts. There is no indication that this is a proxy statement, definitive additional materials filing, or any other regulatory filing type despite the initial header. The content is focused on discussing clinical trial results and company updates in a spoken format, which aligns with a Call Transcript (CT). The document length (15,000 characters) and detailed content confirm it is the full transcript, not just an announcement or summary.
2015-12-11 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used for reporting unscheduled material events or corporate changes. The text includes an announcement of topline results from a pharmacokinetic study and mentions a conference call. It also references an attached press release as an exhibit. The document does not contain detailed financial statements or comprehensive financial analysis, nor is it an earnings release or annual/interim report. It is primarily an event announcement and press release filing. According to the classification rules, such filings are best categorized under Regulatory Filings (RNS) as they do not fit into more specific categories like Earnings Release or Annual Report.
2015-12-10 English
DEFINITIVE ADDITIONAL MATERIALS
Remuneration Information Classification · 95% confidence The document is titled 'DEFA14A' and is described as 'Definitive Additional Materials' related to a Schedule 14A filing, which is a proxy solicitation document under the Securities Exchange Act of 1934. It includes information about a company's clinical study results, a conference call announcement, and references to a previously filed definitive proxy statement for the Annual Meeting of Stockholders. The document is not the proxy statement itself but additional materials related to it. The presence of 'DEFA14A' and the context of proxy solicitation materials clearly indicate this is a Remuneration Information filing or related proxy solicitation material. Given the specific form DEFA14A and the nature of the content, the correct classification is 'DEF 14A' which covers reports detailing compensation and proxy solicitation materials including definitive additional materials.
2015-12-10 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.